Featured Clinical Focus
AML
Biomarker-Driven Lung Cancer
Breast Cancer
CAR T-Cell Therapy
Chronic Lymphocytic Leukemia
EGFR+ Lung Cancer
Follicular Lymphoma
GI Cancers
HCC
HER2-Positive Breast Cancer
Lung Cancer
Lymphomas
Mantle Cell Lymphoma
MPNs
Multiple Myeloma
Prostate Cancer
Renal Cell Carcinoma
Thyroid Cancers
Clinical Focus
Brain Cancer
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Gynecologic Cancers
Head & Neck Cancers
Hematology
Leukemias
Lung Cancer
Lymphomas
Melanoma
Sarcoma
Skin Cancers
Thyroid Cancers
News
All News
Press Releases
Conferences
Conference Coverage
Conference Listing
Media
All Videos
Case-Based Peer Perspectives
Expert Perspective Virtual Tumor Board
Interviews
Investigator Perspectives
Medical World News
Podcasts
Precision Medicine
Publications
All Publications
CBPP Spotlight Live
Evolving Paradigms
Targeted Therapies in Oncology
Resources
Education
Partners
Subscribe
eNewsletter
Search
Featured Clinical Focus
AML
Biomarker-Driven Lung Cancer
Breast Cancer
CAR T-Cell Therapy
Chronic Lymphocytic Leukemia
EGFR+ Lung Cancer
Follicular Lymphoma
GI Cancers
HCC
HER2-Positive Breast Cancer
Lung Cancer
Lymphomas
Mantle Cell Lymphoma
MPNs
Multiple Myeloma
Prostate Cancer
Renal Cell Carcinoma
Thyroid Cancers
Clinical Focus
See All >
Brain Cancer
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Gynecologic Cancers
Head & Neck Cancers
Hematology
Leukemias
Lung Cancer
Lymphomas
Melanoma
Sarcoma
Skin Cancers
Thyroid Cancers
Expanding Options for Relapsed/Refractory HER2+ Metastatic Breast Cancer | Precision Medicine
Dr Mark Pegram and Dr Julie Gralow discuss treatment options in relapsed/refractory HER2+ metastatic breast cancer.
home
EP 1: Treatment Options in HER2+ Metastatic Breast Cancer
EP 2: Trastuzumab Emtansine in HER2+ Breast Cancer
EP 3: Options in Breast Cancer After HER2+ Targeted Therapy
EP 4: Trastuzumab Deruxtecan in HER2+ Breast Cancer
EP 5: Neratinib + Capecitabine in HER2+ Breast Cancer
EP 6: Understanding HER2CLIMB Clinical Trial
EP 7: Toxicity Management When Using HER2CLIMB Regimen
EP 8: Next-Generation Sequencing in HER2+ Breast Cancer
EP 9: Newly Approved Agents for HER2+ Breast Cancer